Psoriasis is a chronic inflammatory systemic disease often associated with comorbidities, a fact that must be taken into account during treatment. Particular attention should be paid to psoriatic arthritis (PsA), chronic inflammatory bowel diseases (IBD), obesity, and cardiometabolic diseases. These specific clinical situations pose a therapeutic challenge and require an individualized and interdisciplinary treatment strategy. The current S3 guideline, among other sources, provides many practice-relevant recommendations in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)